In summary, ABL1 loss may serve as important diagnostic factor predicting more malignant phenotype of AML1-ETO and NUP98-fusions -positive leukemias as well as their unique pharmaceutical vulnerabilities to PI3K, ATR and DNA-PK inhibition. This evidence concerns the gene RUNX1T1 and leukemia.